老虎证券

BRIEF-Prokidney Announces Alignment With The FDA On The Accelerated Approval Pathway For Rilparencel

Reuters
07-15
BRIEF-Prokidney Announces Alignment With The FDA On The Accelerated Approval Pathway For Rilparencel

July 15 (Reuters) - ProKidney Corp PROK.O:

  • PROKIDNEY ANNOUNCES ALIGNMENT WITH THE FDA ON THE ACCELERATED APPROVAL PATHWAY FOR RILPARENCEL

  • PROKIDNEY CORP - FDA CONFIRMS EGFR SLOPE AS SURROGATE ENDPOINT FOR RILPARENCEL IN PATIENTS WITH CKD & TYPE 2 DIABETES

  • PROKIDNEY CORP - TOPLINE DATA FOR ACCELERATED APPROVAL EXPECTED IN Q2 2027

  • PROKIDNEY CORP - FDA CONFIRMS PHASE 3 PROACT 1 STUDY CAN BE USED FOR BOTH ACCELERATED APPROVAL & FOR FULL APPROVAL

Source text: ID:nGNX5bQsS8

Further company coverage: PROK.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10